Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

NCT03790865 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
158
Enrollment
INDUSTRY
Sponsor class

Stopped Livoletide did not result in a statistically significant improvement in hyperphagia and food-related behaviors

Conditions

Interventions

Sponsor

Millendo Therapeutics SAS